Biogen Inc. (BIIB) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$190.68
Price Target
$211.42
Target Range
$143.00 — $260.00
Analyst Rating
Buy
Forward P/E12.9x
Trailing P/E21.6x
Forward PEG—
Implied Growth+58.6%
Median Target$214.00
Analyst Spread55.3%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$143
-25.0%
Consensus
$211
+10.9%
Bull Case
$260
+36.4%
Valuation Model TargetsConfidence: 53/100
Bear$139
Base$248
Bull$570
BIIB Price Target Analysis
Updated May 6, 2026As of May 6, 2026, Biogen Inc. (BIIB) has a Wall Street consensus price target of $211.42, based on estimates from 48 covering analysts. With the stock currently trading at $190.68, this represents a potential upside of +11.8%. The company has a market capitalization of $28.15B.
Analyst price targets range from a low of $143.00 to a high of $260.00, representing a 55% spread in expectations. The median target of $214.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 28 analysts rating the stock as a Buy or Strong Buy,19 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, BIIB trades at a trailing P/E of 21.6x and forward P/E of 12.9x. Analysts expect EPS to grow +58.6% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $247.94, with bear and bull scenarios of $138.67 and $569.55 respectively. Model confidence stands at 53/100, reflecting moderate uncertainty in projections.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+33.5%
Avg Forward P/E24.1x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 REGNRegeneron Pharmaceuticals, Inc. | $74.9B | $720.78 | $865.68 | +23.3% | Buy | 15.2x | 48 |
 VRTXVertex Pharmaceuticals Incorporated | $108.8B | $427.65 | $552.27 | +30.1% | Buy | 22.1x | 56 |
 BMRNBioMarin Pharmaceutical Inc. | $10.5B | $54.60 | $89.64 | +68.4% | Buy | 12.4x | 41 |
 ALNYAlnylam Pharmaceuticals, Inc. | $40.4B | $303.00 | $445.67 | +48.0% | Buy | 45.0x | 52 |
 GILDGilead Sciences, Inc. | $169.8B | $136.30 | $161.88 | +21.3% | Buy | 15.6x | 58 |
 AMGNAmgen Inc. | $178.7B | $331.11 | $350.76 | +6.4% | Buy | 14.8x | 38 |
 INCYIncyte Corporation | $19.9B | $99.85 | $109.50 | +12.3% | Buy | 13.0x | 44 |
 IONSIonis Pharmaceuticals, Inc. | $12.7B | $76.85 | $107.27 | +42.6% | Buy | — | 32 |
 ACADACADIA Pharmaceuticals Inc. | $3.6B | $21.48 | $34.78 | +55.6% | Buy | 50.4x | 37 |
 LLYEli Lilly and Company | $932.6B | $987.11 | $1258.47 | +27.4% | Buy | 28.6x | 45 |
Upside Potential Comparison
BMRNACADALNYIONSVRTXLLYREGNGILDFull BIIB Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See BIIB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BIIB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BIIB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBIIB — Frequently Asked Questions
Quick answers to the most common questions about buying BIIB stock.
What is the BIIB stock price target for 2026?
Biogen Inc. (BIIB) has a consensus 12-month price target of $211.42, implying 11.8% upside from $190.68. The 48 analysts covering BIIB see moderate appreciation potential.
Is BIIB a buy, sell, or hold?
BIIB has a consensus rating of "Buy" based on 48 Wall Street analysts. The rating breakdown is predominantly bullish, with 28 Buy/Strong Buy ratings. The consensus 12-month price target of $211.42 implies 11.8% upside from current levels.
Is BIIB stock overvalued or undervalued?
With a forward P/E of 12.8929x, BIIB trades at a relatively low valuation. The consensus target of $211.42 implies 11.8% appreciation, suggesting meaningful undervaluation.
How high can BIIB stock go?
The most bullish Wall Street analyst has a price target of $260 for BIIB, while the most conservative target is $143. The consensus of $211.42 represents the median expectation. Our quantitative valuation model projects a bull case target of $570 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover BIIB stock?
BIIB is heavily covered by Wall Street, with 48 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 28 have Buy ratings, 19 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the BIIB stock forecast?
The 12-month BIIB stock forecast based on 48 Wall Street analysts shows a consensus price target of $211.42, with estimates ranging from $143 (bear case) to $260 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $248, with bear/bull scenarios of $139/$570.
What is BIIB's fair value based on fundamentals?
Our quantitative valuation model calculates BIIB's fair value at $248 (base case), with a bear case of $139 and bull case of $570. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 53/100.
What is BIIB's forward P/E ratio?
BIIB trades at a forward P/E ratio of 12.9x based on next-twelve-months earnings estimates compared to a trailing P/E of 21.6x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy BIIB stock?
Wall Street analysts are optimistic on BIIB, with a "Buy" consensus rating and $211.42 price target (11.8% upside). 28 of 48 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do BIIB price targets vary so much?
BIIB analyst price targets range from $143 to $260, a 55% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $211.42 consensus represents the middle ground. Our model's $139-$570 range provides an independent fundamental perspective.